Medical experts have renamed Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome, or PMOS, to more accurately describe the condition [1].
This shift in terminology aims to remove misleading language and prioritize the systemic endocrine and metabolic drivers of the syndrome. By dropping the term "polycystic," the medical community seeks to align the name with the actual biological mechanisms affecting patients.
Dr. Laura Riley, chief of OB-GYN at Weill Cornell Medicine and NewYork-Presbyterian, said the transition occurred in New York [2]. The move follows arguments presented in The Lancet and echoed by other medical professionals who believe the previous name focused too heavily on the appearance of the ovaries rather than the underlying metabolic dysfunction [1].
The condition is widespread, affecting one in eight women worldwide [3]. Current estimates suggest approximately 170 million people globally live with the syndrome [4].
Because the condition involves complex interactions between hormones and metabolism, the new name emphasizes the "polyendocrine" nature of the disorder. This means the syndrome involves multiple endocrine glands and processes, rather than being localized solely to the ovaries [1].
Medical professionals said the change is intended to improve diagnostic clarity and patient understanding. The term "polycystic" was often misinterpreted as meaning the presence of cysts, whereas the condition actually involves follicles that have not been released [1].
“The new name better reflects the endocrine and metabolic aspects of the syndrome.”
The transition from PCOS to PMOS represents a shift in the clinical understanding of the disorder from a localized reproductive issue to a systemic metabolic condition. By centering the name on endocrine and metabolic functions, healthcare providers may be able to implement more holistic treatment plans that address insulin resistance and hormonal imbalances rather than focusing primarily on ovarian morphology.
